Related Experiment Video
Updated: Sep 11, 2025
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
Insights
New therapies are improving outcomes for rare genetic dyslipidemias like familial hypercholesterolemia, lipodystrophies, and familial chylomicronemia. Early diagnosis and interdisciplinary care are crucial for managing these serious conditions.
Area of Science:
- Medical Genetics
- Endocrinology
- Cardiovascular Medicine
Background:
- Dyslipidemias are often common but can also be rare, genetically determined disorders.
- Focus on three rare dyslipidemias with new, prognosis-altering therapies: Homozygous Familial Hypercholesterolemia, Lipodystrophies, and Familial Chylomicronemia.
- These conditions, though rare, necessitate early diagnosis and specialized management.
Purpose of the Study:
- To review recent therapeutic advancements for three specific rare dyslipidemias.
- To highlight how novel treatments significantly improve patient outcomes.
- To emphasize the importance of early detection and interdisciplinary collaboration.
Main Methods:
- Review of current literature on rare genetic dyslipidemias.
- Analysis of new therapeutic agents and their impact on disease prognosis.
- Discussion of diagnostic and management strategies.
Main Results:
- Homozygous Familial Hypercholesterolemia: New drugs (evinacumab, lomitapide) improve prognosis by lowering LDL cholesterol and preventing early cardiovascular disease.
- Lipodystrophies: Metreleptin therapy effectively manages metabolic complications associated with adipose tissue loss.
- Familial Chylomicronemia: Volanesorsen reduces triglyceride levels, decreasing the risk of potentially fatal acute pancreatitis.
Conclusions:
- Novel therapies offer significant improvements for patients with rare genetic dyslipidemias.
- Early diagnosis and prompt, interdisciplinary management are critical for optimizing patient care and outcomes.
- Continued research and awareness are essential for addressing these challenging conditions.
Abstract:
Dyslipidemias are mostly considered to be diseases with mass incidence. However, there are also several dyslipidemias that occur within the framework of rare diseases. Most of them are genetically determined. In this review, we have focused on three selected diseases for which new therapy is available and significantly change prognosis of the patients. Homozygous familial hypercholesterolaemia is associated with extreme elevation of LDL cholesterol, leading to premature manifestation of atherosclerotic cardiovascular disease in the first decade of life. Thanks to new hypolipidemic drugs such as evinacumab and lomitapide, patients today have a much better prognosis than in the past. Lipodystrophies are a heterogeneous group of diseases characterized by progressive loss of adipose tissue leading to metabolic abnormalities. Due to new causal metreleptine therapy, we can help patients with managing these metabolic complications significantly. Familial chylomicronemia is not associated with an increased risk of atherosclerotic cardiovascular disease, but it is accompanied by extremely high levels of triglycerides, leading to frequent attacks of acute pancreatitis, which can be potentially fatal. Therapy with volanesorsen leads to a reduction of hypertriglyceridemia, thereby reducing the risk of developing acute pancreatitis. Although these diseases are rare, it is necessary to think about them and diagnose them early. Interdisciplinary cooperation is essential during search and treatment of these patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:18Lipids: Dietary Sources and Requirements
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...